awmsg logo



guanfacine (Intuniv®)


Reference No. 2361

Publication date:
22/06/2016


Appraisal information

guanfacine (Intuniv®) 1 mg prolonged-release tablet
guanfacine (Intuniv®) 2 mg prolonged-release tablet
guanfacine (Intuniv®) 3 mg prolonged-release tablet
guanfacine (Intuniv®) 4 mg prolonged-release tablet


Company: Shire Pharmaceuticals Ltd
BNF category: Central nervous system
NMG meeting date: 13/04/2016
AWMSG meeting date: 18/05/2016
   
   
Submission Type: Full Submission
Status: Not recommended
Advice No: 1216
Ministerial ratification: 20/06/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Guanfacine (Intuniv®) is not recommended for use within NHS Wales for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. The case for cost-effectiveness has not been proven.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download